Saturday 17 October 2026
Export CRBU’s income statement to Excel — free account
Caribou Biosciences, Inc.
CRBU Healthcare Biotechnology
Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue fell 43.8%, EPS grew 58.6% and free cash flow fell 33.2%, each against the same quarter a year earlier.
0.47
0.00
0.00%
Follow CRBU
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 4 | 3 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(5.00) | (1.58) | 3.06 | 2.25 | 5.46 | — | — | — |
P/S ratio |
13.31 | 14.37 | 11.92 | 29.02 | 49.78 | 13.15 | 13.15 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(9.88) | 0.11 | 6.71 | 4.77 | 11.15 | (6.32) | — | — |
P/Operating CF |
(7.13) | (4.05) | (19.23) | (16.05) | (22.34) | (10.16) | (10.16) | — |
Beneish M-Score |
(3.93) | (2.02) | (1.80) | (2.16) | (2.05) | — | — | — |
P/B ratio |
1.22 | 0.57 | 1.12 | 1.34 | 1.23 | 0.00 | 0.00 | — |
Price to Tangible BV |
1.22 | 0.57 | 1.12 | 1.34 | 1.23 | 0.00 | 0.00 | — |
EV/Sales |
0.82 | (6.60) | 2.39 | 11.14 | 10.62 | 2.98 | 2.98 | — |
EV/EBITDA |
0.00 | 0.39 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(0.08) | 0.48 | (0.88) | (1.70) | (3.14) | (2.94) | (2.94) | — |
EV/FCF |
(0.08) | 0.46 | (0.78) | (1.58) | (2.94) | (2.82) | (2.82) | — |
Quick Ratio |
5.56 | 6.90 | 11.70 | 8.89 | 14.81 | 1.60 | 4.47 | — |
Current Ratio |
5.71 | 7.16 | 11.97 | 9.25 | 15.15 | 1.96 | 5.66 | — |
Net Debt/EBITDA |
0.96 | 1.25 | 2.81 | 2.35 | 5.70 | 0.45 | 1.22 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.05 | 0.03 | 0.09 | 0.03 | 0.04 | 0.69 | 0.00 | — |
Operating CF/Net income |
0.75 | 0.93 | 0.91 | 0.92 | 0.49 | 0.97 | 1.37 | — |
Capex/Depreciation |
(0.54) | 6.09 | 12.90 | (7.82) | (2.05) | (0.34) | (1.18) | — |
Interest Coverage |
— | — | — | (23.13) | (452.56) | (1,806.20) | (8,576.25) | — |
| (78.97%) | (47.99%) | (30.50%) | (28.87%) | (36.73%) | 429.55% | 293.36% | — | |
| (60.62%) | (40.00%) | (25.33%) | (24.36%) | (27.98%) | (190.36%) | 0.00% | — | |
ROIC |
0.00% | (239.87%) | (183.29%) | (124.98%) | (349.05%) | (1,168.00%) | 0.00% | — |
Return on Tangible Assets |
(117.02%) | (71.68%) | (31.04%) | (40.95%) | (18.08%) | (222.50%) | (45.71%) | — |
Average Days of Receivables |
64.53 | 76.44 | 25.77 | 63.69 | 252.36 | 113.15 | 251.11 | — |
Research and Development Expense of Revenue |
980.72% | 1,302.31% | 325.07% | 593.68% | 544.44% | 278.50% | 408.34% | — |
Selling, General and Administrative Expense of Revenue |
339.76% | 464.85% | 111.56% | 274.49% | 253.41% | 113.74% | 284.35% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
113.63% | 167.16% | 39.88% | 84.59% | 35.93% | 8.11% | 21.32% | — |
Graham Net Nets |
0.62 | 1.11 | 0.67 | 0.47 | 0.70 | 0.52 | 0.52 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(100.00%) | (103.77%) | (26.03%) | (24.81%) | (23.49%) | (24.06%) | (24.06%) | — |
Free Cash Flow Yield |
(75.66%) | (99.62%) | (25.52%) | (24.24%) | (7.25%) | (8.04%) | (8.04%) | — |
Revenue per Share |
0.12 | 0.11 | 0.47 | 0.23 | 0.30 | 1.45 | 0.69 | — |
Operating CF per Share |
(1.19) | (1.53) | (1.26) | (1.50) | (1.03) | (3.89) | (3.82) | — |
Capex per Share |
(0.01) | (0.05) | (0.16) | (0.11) | (0.07) | (0.04) | (0.11) | — |
Free Cash Flow per Share |
(1.20) | (1.58) | (1.42) | (1.60) | (1.09) | (3.92) | (3.93) | — |
Cash per Share |
1.49 | 2.32 | 4.46 | 4.07 | 11.87 | 1.87 | 4.90 | — |
Shareholders Equity per Share |
1.31 | 2.80 | 4.99 | 4.95 | 12.25 | 2.09 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.31 | 2.80 | 4.99 | 4.95 | 12.25 | 2.09 | 0.00 | — |
Free Cash Flow |
(112.35) | (143.07) | (104.90) | (97.42) | (34.64) | (33.52) | (32.89) | — |
Working Capital |
119.82 | 188.73 | 310.54 | 232.12 | 365.36 | 11.92 | 46.93 | — |
Capital Expenditures |
(1.36) | (4.87) | (11.61) | (6.45) | (2.12) | (0.31) | (0.88) | — |
Net Current Asset Value |
92.04 | 159.02 | 275.03 | 187.35 | 336.66 | 6.15 | 57.01 | — |
EV/EBIT |
0.00 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.12 | 0.49 | 0.34 | 0.47 | 0.22 | 0.02 | 0.15 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.37 | (0.04) | (0.05) | 0.08 | 0.21 | 0.26 | 0.17 | — |
Cash ROIC |
(42.96%) | (30.93%) | (15.05%) | (17.76%) | (4.54%) | (99.06%) | (80.08%) | — |
Accounts Receivable Turnover |
5.49 | 4.42 | 14.21 | 3.06 | 1.83 | 3.16 | 1.27 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
2.03 | 2.26 | 2.43 | 4.53 | 5.23 | 3.91 | 4.57 | — |
Average Payables |
4.13 | 2.80 | 2.13 | 2.57 | 3.30 | 2.57 | 2.57 | — |
Average Assets |
244.34 | 372.76 | 402.99 | 408.06 | 239.20 | 18.02 | 0.00 | — |
Average Common Equity |
187.56 | 310.68 | 334.64 | 344.35 | 182.19 | (7.99) | (7.99) | — |
Columns are period end dates